Literature DB >> 8481934

Cell biological factors associated with the response of breast cancer to systemic treatment.

J G Klijn1, E M Berns, M Bontenbal, J Foekens.   

Abstract

A large number of cell biological parameters are currently available to predict the prognosis of patients with breast cancer, but it is still difficulty accurately to predict the response to treatment. A valuable prognostic factor can be a poor predictive factor for response, and vice versa. High tumor levels of ER, PgR, AR and pS2 predict a relatively good response to endocrine therapy, while EGF-R positively, HER2/neu positivity, aneuploidy, high proliferation indices and possibly high uPA levels indicate a high chance of poor response to endocrine therapy in metastatic breast cancer. With respect to chemotherapy, a high proliferation rate and HER2/neu amplification predict a good response to therapy in metastatic disease, while MDR gene expression and possibly c-myc amplification are related to a worse response. In conclusion, the newer cell biological parameters can be used to select high and low-risk patients, type of systemic treatment, and as targets for new treatment modalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481934     DOI: 10.1016/0305-7372(93)90007-e

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  6 in total

1.  FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.

Authors:  W R Xing; K W Gilchrist; C P Harris; W Samson; L F Meisner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.

Authors:  J G Klijn; M P Look; H Portengen; J Alexieva-Figusch; W L van Putten; J A Foekens
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

3.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

4.  Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.

Authors:  E Niskanen; C Blomqvist; K Franssila; P Hietanen; V M Wasenius
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

Authors:  K Nooter; G Brutel de la Riviere; M P Look; K E van Wingerden; S C Henzen-Logmans; R J Scheper; M J Flens; J G Klijn; G Stoter; J A Foekens
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Authors:  J A Foekens; H Portengen; M P Look; W L van Putten; B Thirion; M Bontenbal; J G Klijn
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.